Influence of smoking and smoking cessation on levels of urinary 11-dehydro thromboxane B2

Toxicology Reports

Volumn 5, Issue , 2018, Pages 561-567

  van der Plas, Angela ^a   Pouly, Sandrine ^a   de La Bourdonnaye, Guillaume ^a   Ng, Wee Teck ^a   Baker, Gizelle ^a   Lüdicke, Frank ^a  

^a PHILIP MORRIS PRODUCTS S A   (Switzerland)

Author keywords

Inflammation; Meta analysis; Smoking; Thromboxane

Indexed keywords

11 OXOTHROMBOXANE B2; THROMBOXANE DERIVATIVE;

CLINICAL OUTCOME; CREATININE BLOOD LEVEL; FOLLOW UP; HUMAN; META ANALYSIS; POPULATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING CESSATION; URINARY EXCRETION;

EID: 85046716250     PISSN: 22147500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxrep.2018.04.005     Document Type: Review

References (49)

1. Calapai, G., Caputi, A.P., Mannucci, C., Gregg, E.O., Pieratti, A., Aurora Russo, G., et al. A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal. Toxicol. 21:13 (2009), 1138–1143, 10.3109/08958370902798455 PubMed PMID: 19852556.
2. Burns, D.M., Epidemiology of smoking-induced cardiovascular disease. Prog. Cardiovasc. Dis. 46:1 (2003), 11–29 PubMed PMID: 12920698.
3. U.S. Department of Health and Human Services, The Health Consequences of Smoking: a Report of the Surgeon General., 2004, US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA.
4. Willett, W.C., Green, A., Stampfer, M.J., Speizer, F.E., Colditz, G.A., Rosner, B., et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N. Engl. J. Med. 317:21 (1987), 1303–1309, 10.1056/NEJM198711193172102 PubMed PMID: 3683458.
5. Gehani, A.A., Al-Hinai, A.T., Zubaid, M., Almahmeed, W., Hasani, M.R., Yusufali, A.H., et al. Association of risk factors with acute myocardial infarction in middle eastern countries: the INTERHEART middle east study. Eur. J. Prev. Cardiol. 21:4 (2014), 400–410, 10.1177/2047487312465525 PubMed PMID: 23125402.
6. Lee, P.N., Fry, J.S., Thornton, A.J., Estimating the decline in excess risk of cerebrovascular disease following quitting smoking–a systematic review based on the negative exponential model. Regul. Toxicol. Pharmacol.: RTP 68:1 (2014), 85–95, 10.1016/j.yrtph.2013.11.013 Epub 2013/12/03, PubMed PMID: 24291341.
7. Lee, P.N., Fry, J.S., Hamling, J.S., Using the negative exponential distribution to quantitatively review the evidence on how rapidly the excess risk of ischaemic heart disease declines following quitting smoking. Regul. Toxicol. Pharmacol.: RTP 64:1 (2012), 51–67, 10.1016/j.yrtph.2012.06.009 PubMed PMID: 22728684.
8. Nowak, J., Murray, J.J., Oates, J.A., FitzGerald, G.A., Biochemical evidence of a chronic abnormality in platelet and vascular function in healthy individuals who smoke cigarettes. Circulation 76:1 (1987), 6–14 PubMed PMID: 3297389.
9. (Administration) FFaD, Philip Morris Products S.A. Modified Risk Tobacco Product (MRTP) Applications – Clinical Risk Endpoints. [cited 2017 August 31 2017]. Available from, 2017 https://www.fda.gov/TobaccoProducts/Labeling/MarketingandAdvertising/ucm546281.htm.
10. Calapai, G., Caputi, A.P., Mannucci, C., Russo, G.A., Gregg, E., Puntoni, R., et al. Cardiovascular biomarkers in groups of established smokers after a decade of smoking. Basic Clin. Pharmacol. Toxicol. 104:4 (2009), 322–328, 10.1111/j.1742-7843.2008.00361.x PubMed PMID: 19175368.
11. Patrono, C., Patrignani, P., Davi, G., Thromboxane biosynthesis and metabolism in cardiovascular and renal disease. J. Lipid Mediat. 6:1-3 (1993), 411–415 PubMed PMID: 8357999.
12. Krause, F.J., Thromboxane concentrations in arterial blood of cigarette smokers and hypertensive subjects. Prog. Clin. Biol. Res. 242 (1987), 155–163 PubMed PMID: 3671380.
13. Schmid, P., Karanikas, G., Kritz, H., Pirich, C., Stamatopoulos, Y., Peskar, B.A., et al. Passive smoking and platelet thromboxane. Thromb. Res. 81:4 (1996), 451–460 Epub 1996/02/15. PubMed PMID: 8907294.
14. Lowe, F.J., Gregg, E.O., McEwan, M., Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin. Chem. Lab Med. 47:3 (2009), 311–320, 10.1515/cclm.2009.069 Epub 2009/08/14, PubMed PMID: 19676143.
15. Saareks, V., Ylitalo, P., Alanko, J., Mucha, I., Riutta, A., Effects of smoking cessation and nicotine substitution on systemic eicosanoid production in man. Naunyn Schmiedebergs Arch. Pharmacol. 363:5 (2001), 556–561 PubMed PMID: 11383717.
16. Hozo, S.P., Djulbegovic, B., Hozo, I., Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 5, 2005, 13, 10.1186/1471-2288-5-13 PubMed PMID: 15840177; PubMed Central PMCID: PMC1097734.
17. Macaskill, P., Walter, S.D., Irwig, L., A comparison of methods to detect publication bias in meta-analysis. Stat. Med. 20:4 (2001), 641–654, 10.1002/sim.698 Epub 2001/02/27, PubMed PMID: 11223905.
18. Andreoli, C., Gregg, E.O., Puntoni, R., Gobbi, V., Nunziata, A., Bassi, A., Cross-sectional study of biomarkers of exposure and biological effect on monozygotic twins discordant for smoking. Clin. Chem. Lab. Med. 49:1 (2011), 137–145, 10.1515/CCLM.2011.009 PubMed PMID: 21083439.
19. Barrow, S.E., Ward, P.S., Sleightholm, M.A., Ritter, J.M., Dollery, C.T., Cigarette smoking: profiles of thromboxane- and prostacyclin-derived products in human urine. Biochim. Biophys. Acta 993:1 (1989), 121–127 PubMed PMID: 2679889.
20. Frost-Pineda, K., Liang, Q., Liu, J., Rimmer, L., Jin, Y., Feng, S., et al. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob. Res. 13:3 (2011), 182–193, 10.1093/ntr/ntq235 PubMed PMID: 21330277.
21. Haswell, L.E., Papadopoulou, E., Newland, N., Shepperd, C.J., Lowe, F.J., A cross-sectional analysis of candidate biomarkers of biological effect in smokers, never-smokers and ex-smokers. Biomarkers 19:5 (2014), 356–367, 10.3109/1354750X.2014.912354 PubMed PMID: 24854418.
22. McAdam, B.F., Byrne, D., Morrow, J.D., Oates, J.A., Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 112:7 (2005), 1024–1029, 10.1161/CIRCULATIONAHA.105.542696 PubMed PMID: 16087791.
23. Uedelhoven, W.M., Rutzel, A., Meese, C.O., Weber, P.C., Smoking alters thromboxane metabolism in man. Biochim. Biophys. Acta 1081:2 (1991), 197–201 PubMed PMID: 1998738.
24. Zedler, B.K., Kinser, R., Oey, J., Nelson, B., Roethig, H.J., Walk, R.A., et al. Biomarkers of exposure and potential harm in adult smokers of 3–7 mg tar yield (Federal Trade Commission) cigarettes and in adult non-smokers. Biomarkers 11:3 (2006), 201–220, 10.1080/13547500600576260 PubMed PMID: 16760130.
25. Uyama, O., Matsui, Y., Shimizu, S., Michishita, H., Sugita, M., Risk factors for carotid atherosclerosis and platelet activation. Jpn. Circ. J. 58:6 (1994), 409–415 PubMed PMID: 8065012.
26. Benowitz, N.L., Fitzgerald, G.A., Wilson, M., Zhang, Q., Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. J. Am. Coll. Cardiol. 22:4 (1993), 1159–1167 PubMed PMID: 7691912.
27. Goncalves, L.H., Silva, M.V., Duarte, R.C., Dusse, L.M., Fernandes, A.P., Bosco, A.A., et al. Acetylsalicylic acid therapy: influence of metformin use and other variables on urinary 11-dehydrothromboxane B2 levels. Clin. Chim. Acta 429 (2014), 76–78, 10.1016/j.cca.2013.11.028 PubMed PMID: 24316050.
28. Lopez, E.P., Rice, C., Weddle, D.O., Rahill, G.J., The relationship among cardiovascular risk factors, diet patterns, alcohol consumption, and ethnicity among women aged 50 years and older. J. Am. Diet. Assoc. 108:2 (2008), 248–256, 10.1016/j.jada.2007.10.043 PubMed PMID: 18237573; Epub 2008/02/02, PubMed Central PMCID: PMC2760339.
29. Reilly, M., Delanty, N., Lawson, J.A., FitzGerald, G.A., Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94:1 (1996), 19–25 PubMed PMID: 8964113.
30. Loke, W.M., Sing, K.L., Lee, C.Y., Chong, W.L., Chew, S.E., Huang, H., et al. Cyclooxygenase-1 mediated platelet reactivity in young male smokers. Clin. Appl. Thromb./Hemost. 20:4 (2014), 371–377, 10.1177/1076029612466284 PubMed PMID: 23242413.
31. Ludicke, F., Magnette, J., Baker, G., Weitkunat, R., A Japanese cross-sectional multicentre study of biomarkers associated with cardiovascular disease in smokers and non-smokers. Biomarkers 20:6-7 (2015), 411–421, 10.3109/1354750X.2015.1096303 PubMed PMID: 26616146.
32. Liu, J., Liang, Q., Frost-Pineda, K., Muhammad-Kah, R., Rimmer, L., Roethig, H., et al. Relationship between biomarkers of cigarette smoke exposure and biomarkers of inflammation, oxidative stress, and platelet activation in adult cigarette smokers. Cancer Epidemiol. Biomark. Prev. 20:8 (2011), 1760–1769, 10.1158/1055-9965.EPI-10-0987 PubMed PMID: 21708936.
33. Ikonomidis, I., Lekakis, J., Vamvakou, G., Andreotti, F., Nihoyannopoulos, P., Cigarette smoking is associated with increased circulating proinflammatory and procoagulant markers in patients with chronic coronary artery disease: effects of aspirin treatment. Am. Heart J. 149:5 (2005), 832–839, 10.1016/j.ahj.2004.08.030 PubMed PMID: 15894964.
34. DeFilippis, A.P., Rai, S.N., Cambon, A., Miles, R.J., Jaffe, A.S., Moser, A.B., et al. Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity. Nutr. Metab. Cardiovasc. Dis. 24:4 (2014), 428–433, 10.1016/j.numecd.2013.08.012 PubMed PMID: 24370448; PubMed Central PMCID: PMC4409424.
35. Uyama, O., Shimizu, S., Nakanishi, T., Nakahama, H., Takiguchi, A., Hayashi, Y., et al. Urinary 11-dehydro-thromboxane B2: a quantitative index of platelet activation in cerebral infarction. Intern. Med. 31:6 (1992), 735–739 PubMed PMID: 1392173.
36. Frost-Pineda, K., Liang, Q., Liu, J., Rimmer, L., Jin, Y., Feng, S., et al. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob. Res., 2011, 10.1093/ntr/ntq235 Epub 2011/02/19, PubMed PMID: 21330277.
37. Rangemark, C., Ciabattoni, G., Wennmalm, A., Excretion of thromboxane metabolites in healthy women after cessation of smoking. Arterioscler. Thromb. 13:6 (1993), 777–782 PubMed PMID: 8499397.
38. Schwarzer, G., Carpenter, J.R., Rucker, G., Fixed effect and random effects meta-analysis. Meta-Anal. R., XII, 2015, 252.
39. McCullough, P.A., Vasudevan, A., Sathyamoorthy, M., Schussler, J.M., Velasco, C.E., Lopez, L.R., et al. Urinary 11-dehydro-thromboxane B2 and mortality in patients with stable coronary artery disease. Am. J. Cardiol. 119:7 (2017), 972–977, 10.1016/j.amjcard.2016.12.004 PubMed PMID: 28139223.
40. Szczeklik, W., Stodolkiewicz, E., Rzeszutko, M., Tomala, M., Chrustowicz, A., Zmudka, K., et al. Urinary 11-dehydro-thromboxane B2 as a predictor of acute myocardial infarction outcomes: results of leukotrienes and thromboxane in myocardial infarction (LTIMI) study. J. Am. Heart Assoc., 5(8), 2016, 10.1161/JAHA.116.003702 PubMed PMID: 27481134; PubMed Central PMCID: PMCPMC5015290.
41. Vasudevan, A., Tecson, K.M., Bennett-Firmin, J., Bottiglieri, T., Lopez, L.R., Peterson, M., et al. Prognostic value of urinary 11-dehydro-thromboxane B2 for mortality: A cohort study of stable coronary artery disease patients treated with aspirin. Catheter. Cardiovasc. Interv., 2017, 1–6, 10.1002/ccd.27437 PubMed PMID: 29193683.
42. Wang, N., Vendrov, K.C., Simmons, B.P., Schuck, R.N., Stouffer, G.A., Lee, C.R., Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease. Prostaglandins Other Lipid Mediat. 134 (2018), 24–31, 10.1016/j.prostaglandins.2017.11.003 PubMed PMID: 29155368; PubMed Central PMCID: PMCPMC5803431.
43. Von Hippel, P.T., The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med. Res. Methodol., 15(35), 2015.
44. Doll, R., Peto, R., Mortality in relation to smoking: 20 years’ observations on male British doctors. Br. Med. J. 2:6051 (1976), 1525–1536 PubMed PMID: 1009386; PubMed Central PMCID: PMCPMC1690096.
45. Prochaska, J.O., DiClemente, C.C., Stages and processes of self-change of smoking: toward an integrative model of change. J. Consult. Clin. Psychol. 51:3 (1983), 390–395 PubMed PMID: 6863699.
46. FDA (Food and Drug Administration), Guidance for Industry–Modified Risk Tobacco Product Applications - Draft Guidance. 2012.
47. Hamberg, M., Svensson, J., Samuelsson, B., Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U. S. A. 72:8 (1975), 2994–2998 PubMed PMID: 1059088; PubMed Central PMCID: PMCPMC432905.
48. Lawson, J.A., Patrono, C., Ciabattoni, G., Fitzgerald, G.A., Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. Anal. Biochem. 155:1 (1986), 198–205 PubMed PMID: 3087234.
49. Walker, E., Hernandez, A.V., Kattan, M.W., Meta-analysis: its strengths and limitations. Cleve Clin. J. Med. 75:6 (2008), 431–439 PubMed PMID: 18595551.